Search hospitals > Illinois > Chicago
Advocate Illinois Masonic Medical Center
Claim this profileChicago, Illinois 60657
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
106 reported clinical trials
19 medical researchers
Summary
Advocate Illinois Masonic Medical Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Skin Cancer, Breast Cancer, Breast cancer, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Advocate Illinois Masonic Medical Center is involved with conducting 106 clinical trials across 290 conditions. There are 19 research doctors associated with this hospital, such as Thomas J. Saphner, Rubina Qamar, Antony Ruggeri, and Sigrun Hallmeyer, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
Top PIs
Thomas J. SaphnerAurora Saint Luke's Medical Center1 year of reported clinical research
Expert in Skin Cancer
Studies Breast Cancer
30 reported clinical trials
68 drugs studied
Rubina QamarAurora Saint Luke's Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Skin Cancer
25 reported clinical trials
70 drugs studied
Antony RuggeriAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Skin Cancer
Studies Colon Cancer
14 reported clinical trials
57 drugs studied
Sigrun Hallmeyer, MDAdvocate Lutheran General Hospital2 years of reported clinical research
Studies Breast Cancer
Studies Skin Cancer
13 reported clinical trials
22 drugs studied
Clinical Trials running at Advocate Illinois Masonic Medical Center
Breast Cancer
Skin Cancer
Lung Cancer
Prostate Cancer
Breast cancer
Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Stomach Cancer
Esophageal cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Advocate Illinois Masonic Medical Center?
Advocate Illinois Masonic Medical Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Skin Cancer, Breast Cancer, Breast cancer, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Advocate Illinois Masonic Medical Center is involved with conducting 106 clinical trials across 290 conditions. There are 19 research doctors associated with this hospital, such as Thomas J. Saphner, Rubina Qamar, Antony Ruggeri, and Sigrun Hallmeyer, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.